Accueil

Zofran

Zofran

Spécifications

103639-04-9Numéro CAS
600-465-5Numéro CE
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochlorideNom IUPAC
C18H24ClN3O3Formule chimique
365.9 g/molMasse molaire
Zofran; RefChem:934563; Ondansetron hydrochloride dihydrate; 103639-04-9; Ondansetron hydrochloride hydrate; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochloride; DTXSID9048857; GR-38032F; Ondansetron (hydrochloride dihydrate); 9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride dihydrate; 4H-Carbazol-4-one,1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-,monohydrochloride, dihydrate; UNII-NMH84OZK2B; Setrodon; Zensana; Zofrene; Yatrox; Zofran Zydis; MFCD00374371; Zofran (TN); Ondansetron hydrochloride [USAN:USP:JAN]; NCGC00016968-01; CAS-103639-04-9; SCHEMBL25018; (+-)-2,3-Dihydro-9-methyl-3-((2-methylimidazol-1-yl)methyl)carbazol-4(1H)-one monohydrochloride dihydrate; CHEBI:7774; HY-B0002AR; Ondansetronhydrochloridedihydrate; orb1308522; CHEMBL3186492; DTXCID6028783; SCHEMBL29387592; HY-B0002A; RHB-102; GLXC-07710; HMS5083F04; Ondansetron (hydrochloride hydrate); Tox21_113345; AC-667; GG-032; s4748; AKOS015994673; Ondansetron for TLC system suitability; CCG-268235; CS-1716; FO26571; GR-C505/75; KS-1091; Ondansetron hydrochloride dihydrate CRS; TO-2061; ONDANSETRON HYDROCHLORIDE [USAN]; ONDANSETRON HYDROCHLORIDE [MART.]; ONDANSETRON HYDROCHLORIDE [VANDF]; AC-30904; BO164178; Ondansetron for LC system suitability CRS; ONDANSETRON HYDROCHLORIDE [USP-RS]; ST024023; Ondansetron for TLC system suitability CRS; DB-040472; O5212; Ondansetron hydrochloride hydrate (JAN/USP); Ondansetron HCl dihydrate - Bio-X trade mark; C71153; D00678; EN300-122610; ONDANSETRON HYDROCHLORIDE [ORANGE BOOK]; ONDANSETRON HYDROCHLORIDE DIHYDRATE [MI]; ONDANSETRON HYDROCHLORIDE HYDRATE [JAN]; Ondansetron (hydrochloride dihydrate) (Standard); ONDANSETRON HYDROCHLORIDE [USP MONOGRAPH]; F869521; ONDANSETRON HYDROCHLORIDE DIHYDRATE [WHO-DD]; Q27284954; ONDANSETRON HYDROCHLORIDE DIHYDRATE [EP MONOGRAPH]; Ondansetron hydrochloride dihydrate, >=98% (HPLC), powder; Ondansetron for LC system suitability, European Pharmacopoeia (EP) Reference Standard; Ondansetron for TLC system suitability, European Pharmacopoeia (EP) Reference Standard; Ondansetron hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard; Ondansetron Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Ondansetron hydrochloride, United States Pharmacopeia (USP) Reference Standard; (+/-)-2,3-DIHYDRO-9-METHYL-3-((2-METHYLIMIDAZOL-1-YL)METHYL)CARBAZOL-4(1H)-ONE MONOHYDROCHLORIDE DIHYDRATE; 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydochloride dihydrate; 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride dihydrate; 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one hydrochloride dihydrate; 4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-, HYDROCHLORIDE, HYDRATE (1:1:2); 4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-, MONOHYDROCHLORIDE, (+/-)-, DIHYDRATE; 9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one hydrochloride dihydrate; 9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride dihydrate (1:1:2); 9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one--hydrogen chloride--water (1/1/2); 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one dihydrate hydrochloride; 9-methyl-3-[(2-methylimidazolyl)methyl]-1,2,3,9-tetrahydro-4aH-carbazol-4-one, chloride, hydrate, hydrate; Ondansetron clorhydrate dihydrateSynonymes